FDA approves GSK’s Hibsago for chronic hepatitis B

PUBT · 2d ago
FDA approves GSK’s Hibsago for chronic hepatitis B
  • FDA approved GSK’s Hibsago (bepirovirsen) for chronic hepatitis B in eligible adults without cirrhosis.
  • The six-month treatment is used with nucleos(t)ide analogue therapy, with self-administration available following the first dose.
  • Phase III trials showed a 19% functional cure rate versus 0% with placebo in patients with HBsAg levels ≤3,000 IU/ml.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GSK plc published the original content used to generate this news brief on October 20, 2026, and is solely responsible for the information contained therein.